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WG Interpretation of MERCK Data
 Encouraging evidence for effectiveness in prevention of EVD when 
administered in an outbreak setting using a ring-vaccination strategy
 Acceptable safety profile
 Arthritis was an adverse event in a subset of study participants 
(Europe, U.S.)
 No known immune correlate for protection
 EBOV-GP specific IgG antibodies can persist in vaccinees up to 24 
months
Vaccine Safety Discussion Points
 Virus dissemination and replication (skin, joints) can occur and persist for 
up to 2-3 weeks after vaccination
–
–
Seeding of rVSV-ZEBOV into joints as demonstrated by detection of 
rVSV DNA in synovial fluid
Replicating rVSV-ZEBOV recovered from skin vesicles (culture)
 Pathophysiology of chimeric rVSV-ZEBOV vaccine may include features 
attributable to both its VSV and ZEBOV glycoprotein components; may 
play a role in the development of arthralgia/arthritis
Agnandji et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe NEJM 2016
Anticipated Next Steps
 GRADE and Evidence to Recommendations Framework
 Presentation of policy options
 Vote on policy options, pending vaccine licensure, February 2020
– Potential for an emergency meeting in the event the vaccine is not 
licensed by February 2020
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
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